R

Roche

Global pharmaceuticals and diagnostics company

Global Medical Collaboration Leader - Metabolism, China

Full-Time
No salary listed
Expert
Master's, MBA, PharmD, PhD, MD
Shanghai, China
In PersonCandidates should be based in or relocate to Shanghai; relocation support is not offered. National and some international travel is required.
Biology & Biotech

About the job

Requirements
  • A Master Degree in science or a related field is required.
  • Significant experience in the pharmaceutical or related industry at global or affiliate level is required.
  • Experience in Medical Affairs, Product Development or Early Development, including understanding and experience of clinical-trial processes and procedures, is essential.
  • Substantial experience in a medical/scientific field customer-facing role is required.
  • Fluency in written and spoken English is mandatory.
  • Fluency in the written and spoken language of the host country is mandatory; native speakers are strongly preferred.
  • Deep scientific knowledge of one or more disease areas within the metabolic disease spectrum (obesity, diabetes, ASCVD, heart failure) is required.
  • Knowledge of overall drug development and lifecycle processes, and experience in developing and implementing clinical trials and/or other data-generation activities, is required.
  • Knowledge of global and local regulations, guidelines, SOPs, GXP standards, and relevant business intelligence resources is required.
  • Solid knowledge of drug safety/pharmacovigilance and Roche internal SOPs related to this area is required.
  • Ability to demonstrate Roche Values, Leadership Commitments, and VACC leadership is required.
  • Customer-centric behaviors and the ability to build sustainable relationships with internal and external stakeholders are required.
  • Strong data comprehension, critical appraisal, synthesis, interpretation, and delivery skills are required.
  • Ability to monitor the external landscape and communicate trends, competitive activity, risks, and opportunities is required.
  • Ability to collaborate effectively in global, virtual, line, and matrix teams across diverse geographic areas, business settings, and cultures is required.
  • Project management skills and the ability to lead projects to successful conclusion with initiative and accountability are required.
  • Problem-solving skills and an outcome-focused entrepreneurial mindset are required.
  • Influencing and negotiating skills, including the ability to influence without direct authority, are required.
  • Strategic skills and system awareness are required for liaison with teams within PD, pRED/gRED, GPS, Pharma International, and affiliates.
  • Adaptability to evolving business needs and transition across diverse disease areas, functions, and specialized topics is required.
  • The role requires in-field presence, including national and some international travel, and regular customer meetings.
Responsibilities
  • Develop and facilitate relationships and collaborative networks with external stakeholders, ensuring Roche is a preferred partner and promoting a One Roche approach.
  • Establish and maintain trusted relationships with therapeutic area experts, patient organisations, global and local scientific societies, academia, and policy and access stakeholders, in accordance with applicable SOPs and regulations.
  • Represent Roche to scientific stakeholders and act as an ambassador for the organisation’s values, including as the in-field medical point of contact for external stakeholders in assigned geographies.
  • Drive external scientific knowledge exchange with experts in assigned countries, including medical education activities as appropriate.
  • Identify, catalyse, and progress opportunities for medical initiatives and partnerships with internal and external stakeholders at global and affiliate levels.
  • Support the HCX strategy by providing insights that enable a customer-centric approach and by using available communication channels to optimize customer experience.
  • Contribute to disease area medical team therapeutic-area-expert engagement initiatives and outcomes, executing activities with customer centricity.
  • Monitor internal and external developments, trends, and dynamics relevant to assigned disease areas, including digital health, personalized medicine, and patient- and healthcare-ecosystem-centricity.
  • Work with global and affiliate Clinical Operations and Clinical Science teams across PD, gRED, and pRED to coordinate study deployment, site identification, selection, and engagement.
  • Depending on experience, knowledge, and capacity, represent the GMCL team for clinical trials in global forums and study management teams, collaborating with affiliate field medical teams such as MSLs and MSPs.
  • Align disease-area priorities within cross-functional teams and identify potential priority mismatches between internal stakeholders and trial sites.
  • Engage clinical-trial sites in scientific discussions related to disease areas and molecules to support patient recruitment and retention and maintain site staff confidence and motivation.
  • Build partnerships with investigators and site staff through virtual and in-person channels, including site visits, investigator meetings, receptions, and national and international congresses.
  • Suggest or implement approaches to optimize or accelerate trial design, start-up, recruitment, retention, and data collection with internal and external partners.
  • Gather and share investigator and site-staff feedback and insights to optimize clinical-development performance and customer experience.
  • Identify global and local data gaps to inform the IEP.
  • Discuss and support investigator-initiated studies, compassionate-use programmes, and data strategies that support access activities in alignment with disease-area and asset strategies.
  • Collaborate with internal colleagues to define insight-collection strategy, including listening priorities, field support for the Integrated Insight Plan, and aggregation, distribution, and discussion of insight reports.
  • Conduct insight-gathering activities to address knowledge gaps, such as advisory boards, steering committees, proactive plans, and external customer surveys.
  • Disseminate key insights to business partners through agreed channels, gather feedback, and optimize data-driven recommendations.
  • Map and profile external stakeholders to inform engagement plans aligned with customer needs and preferences, using appropriate systems and tools.
  • Build understanding of local environments and surface customer perspectives, beliefs, and behaviors for strategic and tactical decisions.
  • Update the organization on disease-area developments, the competitive landscape, clinical practices and management, research, and patient/carer experience.
  • Use technological advances, including AI and internal systems and tools, to improve compliant insight collection, aggregation, and distribution.
  • Act as a disease-area champion and support affiliate awareness and engagement, including staff training with global and affiliate teams.
  • Support affiliate introduction to assigned disease areas by accelerating understanding of the disease-area ecosystem.
  • Lead or contribute to global or local work packages that incorporate the external customer perspective.
  • Support alignment with global strategy to inform affiliate planning and decision-making.
  • Support or drive local implementation of field-based activities defined within DACS and CORP, collaborating with global and affiliate colleagues and complying with local requirements.
  • Integrate into affiliate practices and culture as a member of the local cross-functional team.
  • Provide above-country medical expertise to support affiliate medical launch and access, engage leading therapeutic-area experts where local medical resources are limited or absent, and share expertise and training with local staff.
  • Where applicable, facilitate handover to affiliate colleagues by sharing local insights, training new staff, and supporting customer and staff connections.
  • Participate in GMC Community initiatives to develop approaches that improve customer engagement and experience.
  • Follow applicable SOPs, systems, and tools, including those for tracking customer interactions and collecting insights.
  • Foster a psychologically safe work environment and promote open feedback within the disease-area team and wider community.
  • Collaborate with teammates, share best practices, and contribute to team- and function-specific working practices, standards, and innovation.
  • Contribute to onboarding new team members and continuous learning activities, such as journal clubs and congress updates.
Desired Qualifications
  • A postgraduate degree such as a PhD, PharmD, MSc, MD, or MBA is highly desirable.
  • Experience in the cardiovascular disease area is preferred.
  • Native-speaker proficiency in the host-country language is strongly preferred.
  • Candidates based in or willing to relocate to Shanghai are preferred.

About the company

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Enicepatide delivered 15.5% weight loss in September 2026 and 22.7% in June.
  • pTau217 can scale immediately through Roche's existing lab network and improve Alzheimer diagnostics.
  • Roche's June 2026 data and September 2026 filings signal multiple obesity shots on goal.

What critics are saying

  • Eli Lilly and Novo Nordisk dominate obesity pricing, distribution, and physician mindshare today.
  • Enicepatide remains Phase II-only; Roche starts late-stage glycemic and cardiovascular studies in 2027.
  • If enicepatide disappoints, Roche burns its $2.7 billion Carmot bet and loses obesity credibility.

What makes Roche unique

  • Roche combines pharma, diagnostics, and installed cobas labs across 4,500 U.S. instruments.
  • Elecsys pTau217 won FDA clearance on August 24, 2026, and CE marking September 7.
  • Roche controls obesity assets from Carmot and Zealand, spanning GLP-1/GIP and amylin.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Performance Bonus

Company News

Yahoo Finance
Oct 16th, 2026
FDA approves Roche's Enspryng as first at-home injection for thyroid eye disease

Roche said the US Food and Drug Administration (FDA) has approved Enspryng (satralizumab) for adults with thyroid eye disease (TED). It is the first and only at-home subcutaneous treatment for the condition, and a patient or caregiver can administer it after training. In the Phase III SatraGO-2 trial, 52.9% of active TED patients on Enspryng had a proptosis (eye bulging) response, against 23.4% on placebo. Double vision fell in 60.7% of patients, against 25.8%. The SatraGO-1 trial missed its primary endpoint at Week 24. No new safety signals emerged. TED affects about 155 in every 100,000 people in the US. This is Enspryng's second approval, after neuromyelitis optica spectrum disorder in 2020. The FDA is also reviewing it for myelin oligodendrocyte glycoprotein antibody-associated disease, with a decision expected in January 2027.

Yahoo Finance
Oct 9th, 2026
FDA approves Roche's Tecentriq for stage III colon cancer, cutting recurrence risk by 50%

The US Food and Drug Administration has approved Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III deficient DNA mismatch repair colon cancer. This marks Tecentriq's twelfth approved indication in the US. The approval follows the phase III ATOMIC study, published in The New England Journal of Medicine, which demonstrated that Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. The 36-month disease-free survival rate was 86% with the combination versus 76% with chemotherapy alone. Nearly 25% of colon cancers are diagnosed at stage III, and almost one in three stage III patients experience recurrence within five years. This represents the first approved adjuvant immunotherapy regimen for this patient population. Roche is pursuing further regulatory filings, including with the European Medicines Agency.

Yahoo Finance
Sep 30th, 2026
Roche's enicepatide shows 22.5% weight loss in 48 weeks, challenging Eli Lilly and Novo Nordisk

Roche posted strong Phase 2 results for its weight loss drug enicepatide, showing 22.5% mean weight loss over 48 weeks. This compares favourably to Eli Lilly's Zepbound, which achieved 20.2% weight loss over 72 weeks in a separate trial. In another Phase 2 study, enicepatide demonstrated HbA1c reductions of up to 2.65 percentage points in diabetic patients after 48 weeks, compared to tirzepatide's 2.37 percentage points after 52 weeks. Despite promising results, Roche faces stiff competition from Novo Nordisk and Eli Lilly, which both have deep pipelines in development. Novo Nordisk's CagriSema is nearing approval, whilst Eli Lilly's retatrutide has posted strong Phase 3 results. Roche's revenue grew 6% year over year in the first half of the year to 30.4 billion Swiss francs.

PR Newswire
Sep 30th, 2026
Roche launches newborn screening test for SMA, SCID and sickle cell disease

Roche has launched a newborn screening test that simultaneously detects three severe genetic conditions: Spinal Muscular Atrophy, Severe Combined Immunodeficiency Disease, and Sickle Cell Disease. TIB MOLBIOL, a Roche subsidiary, developed the LightMix Newborn TREC/SMN1/HBB kit for use in countries accepting the CE mark. The test enables early detection before symptoms appear, allowing clinicians to initiate life-changing treatments sooner. Early intervention can prevent severe nerve damage in SMA, enable lifesaving bone marrow transplants for SCID, and drastically lower infant mortality in SCD through preventive measures. The IVDR-approved test provides a ready-to-use solution that integrates into existing laboratory workflows. It runs on established LightCycler systems, making it accessible for private and academic hospital laboratories across Europe.

Yahoo Finance
Sep 13th, 2026
Roche's Tam-Peli cuts death risk by 54% in Chinese SCLC trial, global phase III studies planned

Roche's collaborator MediLink has announced positive phase III results for tambotatug pelitecan (Tam-Peli) in Chinese patients with relapsed small-cell lung cancer. The TAISHAN-302 trial showed Tam-Peli reduced the risk of death by 54% compared to topotecan, with median overall survival of 13.3 versus 9.4 months. The antibody-drug conjugate also demonstrated superior progression-free survival (7.4 versus 2.8 months) and objective response rates (59.1% versus 9.7%). China's National Medical Products Administration has accepted the New Drug Application for filing. Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong and Macau, with plans to rapidly initiate global trials. The therapy has received Breakthrough Therapy Designations from both the US FDA and China CDE for relapsed small-cell lung cancer.